Research programme: immunotherapeutics - MacroGenics
Latest Information Update: 04 Nov 2017
At a glance
- Originator MacroGenics
- Class Monoclonal antibodies; Viral vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infections
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Infections in USA (Parenteral)
- 04 Feb 2008 Preclinical development for infectious diseases is ongoing
- 07 Jun 2002 Preclinical trials in Autoimmune disorders in USA (unspecified route)